Literature DB >> 8471593

Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.

P L Witt1, B E Storer, G T Bryan, R R Brown, M Flashner, A T Larocca, C B Colby, E C Borden.   

Abstract

Interferons (IFNs) induce gene regulation in vivo that may be used to identify effective doses, schedules, and potential correlates of therapeutic response. To critically examine minimum effective dose, duration of response, and cumulative effects of repetitive doses, a range of subcutaneous doses of IFN beta ser was studied in 32 healthy human volunteers. IFN-induced products of gene regulation assessed were beta 2-microglobulin, neopterin, and tryptophan in serum and 2',5'-oligoadenylate (2-5A) synthetase activity in peripheral blood mononuclear cells. Eight subjects per group received 0.09, 0.9, 9, or 45 MU of IFN beta. Responses were measured at 24, 48, and 72 h after single and multiple doses. The lowest biologically effective dose was 0.9 MU; significant (p < 0.02) increases were observed at 24 h in beta 2-microglobulin and cellular 2-5A synthetase activity. At the two higher doses, 9 and 45 MU, changes were observed at 24 h in all products (p < 0.01). A dose response (p < 0.01) over the range of 0.09-45 MU was observed for all these serum and intracellular gene products. Changes in neopterin, beta 2-microglobulin, and cellular 2-5A synthetase correlated significantly with each other. The response to a single dose of IFN beta was as great in magnitude as the response to multiple doses, suggesting an alternate-day schedule would maintain biological response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471593     DOI: 10.1097/00002371-199304000-00006

Source DB:  PubMed          Journal:  J Immunother Emphasis Tumor Immunol        ISSN: 1067-5582


  9 in total

Review 1.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Is multiple sclerosis a disease that requires frequent beta interferon dosing?

Authors:  Luca Durelli
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

3.  Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Authors:  S Khakoo; P Glue; L Grellier; B Wells; A Bell; C Dash; I Murray-Lyon; D Lypnyj; B Flannery; K Walters; G M Dusheiko
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

Review 4.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

5.  Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.

Authors:  Francesca Gilli; Fabiana Marnetto; Guglielmo Stefanuto; Valentina Rinaldi; Federica Farinazzo; Simona Malucchi; Marco Capobianco; Marzia Caldano; Arianna Sala; Antonio Bertolotto
Journal:  Mol Diagn       Date:  2004

Review 6.  Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.

Authors:  D S Goodin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

Authors:  A Bertolotto; A Sala; S Malucchi; F Marnetto; M Caldano; A Di Sapio; M Capobianco; F Gilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

8.  Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.

Authors:  Ji I Lee; Stephen P Eisenberg; Mary S Rosendahl; Elizabeth A Chlipala; Jacquelyn D Brown; Daniel H Doherty; George N Cox
Journal:  J Interferon Cytokine Res       Date:  2013-08-20       Impact factor: 2.607

9.  Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis.

Authors:  Mohammed K Sharief
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.